Y Combinator-backed AOA Raises $2.5 Million In Seed Funding To Develop First Non-Invasive Test Set To Revolutionize The Future Of Ovarian Cancer Diagnostics When detected early, almost 95% of ovarian cancer patients live more than five years after their diagnosis . AOA is a company on a mission to improve the early detection of cancer through the development of an innovative blood-based platform.